Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in active ankylosing spondylitis
2017-000431-14Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in ankylosing spondylitis (AS) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Proportion of participants with ASAS40 response at Week 14. Started Jul 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2017-000431-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000431-14.